Pharsight

Spravato generic

Spravato is a nasal spray owned by Janssen Pharms. This drug was first authorized for market use on 5th March 2019 and it contains esketamine hydrochloride. Spravato has been granted a total of six patents, none of which have expired yet.

When will Spravato generic be available?

A generic version of Spravato may become available after the 10th of September, 2035. This date is based on the expiration of the patent with the latest end date.

Spravato uses

Spravato can be used as a treatment for treatment-resistant depression (TRD) in adults, in conjunction with an oral antidepressant. It is also effective in mitigating depressive symptoms in adults suffering from major depressive disorder (MDD) who exhibit acute suicidal ideation or behavior. The drug is administered nasally, often as 56mg or 84mg of Esketamine twice weekly for four weeks, followed by a similar dosage either weekly or once every two weeks during the maintenance phase.

Spravato patent expiration

Spravato dosage

Want to ask something?